Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New antithrombotics with an indazole structure.

Ali Kemal Yildiz1, Klaus Rehse, Johannes-Peter Stasch

  • 1Institut für Pharmazie, Freie Universität Berlin, Berlin, Germany.

Archiv Der Pharmazie
|June 10, 2004
PubMed
Summary

New indazole derivatives show promise in preventing blood clots. Compounds (4f) and (4g) inhibited platelet aggregation, while (4j) reduced thrombi formation in rats, likely by inhibiting phosphodiesterase 5 (PDE 5).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Concise Guide to PHARMACOLOGY 2025/26: Enzymes.

British journal of pharmacology·2025
Same author

The Concise Guide to PHARMACOLOGY 2025/26: Catalytic receptors.

British journal of pharmacology·2025
Same author

The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase.

European respiratory review : an official journal of the European Respiratory Society·2024
Same author

The Concise Guide to PHARMACOLOGY 2023/24: Enzymes.

British journal of pharmacology·2023
Same author

The Concise Guide to PHARMACOLOGY 2023/24: Catalytic receptors.

British journal of pharmacology·2023
Same author

Identification and characterization of the new generation soluble guanylate cyclase stimulator BAY-747 designed for the treatment of resistant hypertension.

British journal of pharmacology·2023

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Cardiovascular Research

Background:

  • Blood platelet aggregation is a key factor in thrombosis.
  • Indazole derivatives are explored for their potential therapeutic properties.
  • Understanding mechanisms of anti-thrombotic agents is crucial for drug development.

Purpose of the Study:

  • To synthesize and evaluate novel indazole derivatives for anti-thrombotic activity.
  • To identify specific compounds with potent inhibition of platelet aggregation and thrombi formation.
  • To elucidate the mechanism of action of the most effective indazole derivatives.

Main Methods:

  • Synthesis of fifteen novel indazole derivatives.
  • Assessment of anti-platelet activity using the Born assay (collagen-induced aggregation).

Related Experiment Videos

  • In vivo evaluation of anti-thrombotic effects in rat models (arterioles and venules).
  • Investigation of the mechanism of action, including soluble guanylate cyclase (sGC) activation and phosphodiesterase 5 (PDE 5) inhibition.

    • Main Results:

    • Compounds (4f) and (4g) demonstrated significant inhibition of collagen-induced platelet aggregation (IC50 = 85 and 90 µM, respectively).
    • Oral administration of three derivatives in rats (60 mg/kg) significantly inhibited thrombi formation in both arterioles and venules.
    • Compound (4j) exhibited the strongest in vivo effect, with 15% inhibition in arterioles and 7% in venules.
    • Compound (4j) was found not to activate soluble guanylate cyclase, suggesting a different mechanism.

    Conclusions:

    • Novel indazole derivatives possess significant anti-platelet and anti-thrombotic properties.
    • Compound (4j) shows potential as an anti-thrombotic agent, with its effects likely mediated through phosphodiesterase 5 (PDE 5) inhibition.
    • These findings warrant further investigation into indazole derivatives for cardiovascular applications.